[1]王朋, 吴志鸿. 角膜碱烧伤的药物治疗研究进展[J]. 中国急救复苏与灾害医学杂志, 2016, 11(7): 735-738.
[2]George PM, Wells AU. Pirfenidone for the treatment of idiopathic pulmonary fibrosis[J]. Expert Rev Clin Pharmacol, 2017, 10(5): 483-491.
[3]付麟紫, 吴晓梅. 特发性肺纤维化药物治疗推荐[J]. 中华老年多器官疾病杂志, 2017, 16(3): 234-237.
[4]陈钰清, 闫永吉, 仇美华, 等. 吡非尼酮治疗肺纤维化的疗效与安全性meta分析[J]. 临床药物治疗杂志, 2016, 14(4): 13-22.
[5]Wilson SE. Corneal myofibroblast biology and pathobiology: generation, persistence, and transparency[J]. Exp Eye Res, 2012, 99(1): 78-88.
[6]陈俊杰, 吴共发, 林俊汕, 等. 吡非尼酮对大鼠角膜基质细胞增殖的影响[J]. 国际眼科杂志, 2015, 15 (2): 201-204.
[7]吴共发, 邱丽浈, 曾宇婷, 等. 自制吡非尼酮滴眼液局部应用于角膜的安全性研究[J]. 中华眼科医学杂志(电子版), 2017, 7(6): 250-256.
[8]白军强,赵世红,秦海峰,等.枸橼酸-磷酸氢二钠缓冲液冲洗对小鼠急性角膜化学伤眼表的保护作用[J].中华实验眼科杂志,2017,35(2):122-127.
[9]Li C, Han R, Kang L, et al. Pirfenidone controls the feedback loop of the AT1R/p38 MAPK/renin-angiotensin system axis by regulating liver X receptor-α in myocardial infarction-induced cardiac fibrosis[J]. Sci Rep, 2017, 7: 40523.
[10]Seniutkin O, Furuya S, Luo YS, et al. Effects of pirfenidone in acute and sub-chronic liver fibrosis, and an initiation-promotion cancer model in the mouse[J]. Toxicol Appl Pharmacol, 2018, 339: 1-9.
[11]Li Z, Liu X, Wang B, et al. Pirfenidone suppresses MAPK signalling pathway to reverse epithelial-mesenchymal transition and renal fibrosis[J]. Nephrology (Carlton), 2017, 22(8): 589-597.
[12]陈钰清, 闫永吉, 仇美华, 等. 吡非尼酮抗纤维化作用的研究进展[J]. 临床药物治疗组杂志, 2016, 14(5): 1-7.
[13]李亨辉, 李云端, 邵毅, 等. 吡非尼酮滴眼液在兔眼青光眼手术中的应用研究[J]. 中国实用眼科杂志, 2015, 33(10): 1179-1184.
[14]Chowdhury S, Guha R, Trivedi R, et al. Pirfenidone nanoparticles improve corneal wound healing and prevent scarring following alkali burn[J]. PLoS One, 2013 , 8(8): e70528.
[15]Fink MK,Giuliano EA,Tandon A,et al.Therapeutic potential of Pirfenidone for treating equine corneal scarring[J].Vet Ophthalmol,2015,18(3):242-250.
[16]Gibson DJ, Schultz GS. A corneal scarring model[J]. Methods Mol Biol, 2013, 1037: 277-298.
[17]Tandon A, Tovey JC, Sharma A, et al. Role of transforming growth factor beta in corneal function, biology, and pathology[J]. Curr Mol Med, 2010, 10: 565-578.
[18]张露,李霞. TGF-β在角膜损伤修复中的时间和空间分布[J]. 眼科新进展, 2017, 37(2): 184-188.
[19]Ljubimov AV, Saghizadeh M. Progress in corneal wound healing [J]. Prog Retin Eye Res, 2015, 49(6): 17-45.
[20]刘晓坤, 赵平. 角膜新生血管的发病机制[J]. 眼科新进展, 2006, 26(3): 230-233. |